Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.

Cervera N, Lhoumeau AC, Adélaïde J, Guille A, Murati A, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V.

Haematologica. 2019 Oct 10. pii: haematol.2019.231142. doi: 10.3324/haematol.2019.231142. [Epub ahead of print]

2.

Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.

Wanquet A, Courtier F, Guille A, Carbuccia N, Garnier S, Adélaide J, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Birnbaum D, Murati A.

Leuk Lymphoma. 2019 May;60(5):1289-1293. doi: 10.1080/10428194.2018.1522437. Epub 2019 Jan 2. No abstract available.

PMID:
30601073
3.

Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.

Seguier J, Gelsi-Boyer V, Ebbo M, Hamidou Z, Charbonnier A, Bernit E, Durand JM, Harlé JR, Vey N, Schleinitz N.

Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5. Review.

PMID:
30408583
4.

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Cervera N, Carbuccia N, Mozziconacci MJ, Adélaïde J, Garnier S, Guille A, Murati A, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68. No abstract available.

5.

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A.

Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. No abstract available.

6.

Epigenetically centered evolution in an example of myeloid malignancy.

Adélaide J, Cervera N, Carbuccia N, Garnier S, Guille A, Mozziconnaci MJ, Devillier R, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Am J Hematol. 2016 Sep;91(9):E361-2. doi: 10.1002/ajh.24450. Epub 2016 Jul 4. No abstract available.

7.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
8.

Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.

Cervera N, Carbuccia N, Garnier S, Guille A, Adélaïde J, Murati A, Vey N, Mozziconacci MJ, Chaffanet M, Birnbaum D, Gelsi-Boyer V.

Leukemia. 2016 Apr;30(4):966-70. doi: 10.1038/leu.2015.198. Epub 2015 Jul 23. No abstract available.

PMID:
26202927
9.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

10.

Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML).

Coppin E, Gelsi-Boyer V, Morelli X, Cervera N, Murati A, Pandolfi PP, Birnbaum D, Nunès JA.

Leukemia. 2015 Feb;29(2):500-2. doi: 10.1038/leu.2014.288. Epub 2014 Sep 25. No abstract available.

11.

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.

Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N.

Am J Hematol. 2015 Jan;90(1):E22-4. doi: 10.1002/ajh.23850. Epub 2014 Oct 18. No abstract available.

12.

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.

Cervera N, Itzykson R, Coppin E, Prebet T, Murati A, Legall S, Vey N, Solary E, Birnbaum D, Gelsi-Boyer V.

Am J Hematol. 2014 Jun;89(6):604-9. doi: 10.1002/ajh.23702. Epub 2014 Apr 10.

13.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, Itzykson R, Sanada M, Shiraishi Y, Gelsi-Boyer V, Renneville A, Miyano S, Mori H, Shih LY, Park S, Dreyfus F, Guerci-Bresler A, Solary E, Rose C, Cheze S, Prébet T, Vey N, Legentil M, Duffourd Y, de Botton S, Preudhomme C, Birnbaum D, Bernard OA, Ogawa S, Fontenay M, Kosmider O.

Blood. 2013 Oct 31;122(18):3169-77. doi: 10.1182/blood-2012-11-469619. Epub 2013 Sep 18.

PMID:
24047651
14.

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Adélaide J, Gelsi-Boyer V, Arnoulet C, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Murati A.

Haematologica. 2014 Jan;99(1):37-45. doi: 10.3324/haematol.2013.091454. Epub 2013 Aug 30.

15.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E.

J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.

PMID:
23690417
16.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, Gelsi-Boyer V, de Botton S, Vey N, Preudhomme C, Clavert A, Delabesse E, Park S, Birnbaum D, Fontenay M, Bernard OA, Solary E.

Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5. No abstract available.

PMID:
23443343
17.

Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Prebet T, Charbonnier A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N.

Leuk Lymphoma. 2013 Jul;54(7):1538-40. doi: 10.3109/10428194.2012.744455. Epub 2012 Nov 29. No abstract available.

PMID:
23110702
18.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.

19.

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.

Brecqueville M, Cervera N, Adélaïde J, Rey J, Carbuccia N, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V, Murati A.

Blood Cancer J. 2011 Aug;1(8):e33. doi: 10.1038/bcj.2011.31. Epub 2011 Aug 26. No abstract available.

20.

Myeloid malignancies: mutations, models and management.

Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D.

BMC Cancer. 2012 Jul 23;12:304. doi: 10.1186/1471-2407-12-304. Review.

21.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

22.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
23.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.

J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. Review.

24.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17.

PMID:
22343920
25.

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adélaïde J, Chaffanet M, Rey J, Vey N, Mozziconacci MJ, Birnbaum D.

Blood Cancer J. 2011 May;1(5):e18. doi: 10.1038/bcj.2011.15. Epub 2011 May 13. No abstract available.

26.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.

PMID:
21494260
27.

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.

PMID:
20880116
28.

Alteration of cohesin genes in myeloid diseases.

Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ, Chaffanet M.

Am J Hematol. 2010 Sep;85(9):717-9. doi: 10.1002/ajh.21798.

29.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ.

BMC Cancer. 2010 Aug 2;10:401. doi: 10.1186/1471-2407-10-401.

30.

Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.

Adélaïde J, Gelsi-Boyer V, Rocquain J, Carbuccia N, Birnbaum DJ, Finetti P, Bertucci F, Mozziconacci MJ, Vey N, Birnbaum D, Chaffanet M.

Leukemia. 2010 Aug;24(8):1539-41. doi: 10.1038/leu.2010.135. Epub 2010 Jun 17. No abstract available.

PMID:
20555362
31.

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M.

Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8. No abstract available.

PMID:
20376084
32.

Myelodysplastic syndromes: lost between two states?

Acquaviva C, Gelsi-Boyer V, Birnbaum D.

Leukemia. 2010 Jan;24(1):1-5. doi: 10.1038/leu.2009.157. No abstract available.

PMID:
20068572
33.

Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.

Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélaïde J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ.

Leukemia. 2010 Feb;24(2):469-73. doi: 10.1038/leu.2009.218. Epub 2009 Oct 29. No abstract available.

PMID:
19865112
34.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies.

Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1.

35.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7.

PMID:
19666869
36.

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2009 Jun;145(6):788-800. doi: 10.1111/j.1365-2141.2009.07697.x. Epub 2009 Apr 15.

PMID:
19388938
37.

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.

Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M.

BMC Cancer. 2008 Oct 16;8:299. doi: 10.1186/1471-2407-8-299.

38.

Alterations of NFIA in chronic malignant myeloid diseases.

Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adélaïde J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D.

Leukemia. 2009 Mar;23(3):583-5. doi: 10.1038/leu.2008.228. Epub 2008 Aug 28. No abstract available.

PMID:
18754024
39.

Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes.

Gelsi-Boyer V, Cervera N, Bertucci F, Trouplin V, Remy V, Olschwang S, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D.

Leukemia. 2007 Nov;21(11):2359-62. Epub 2007 Jun 14. No abstract available.

PMID:
17568812
40.

Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.

Etienne A, Gelsi-Boyer V, Carbuccia N, Adélaïde J, Barba G, La Starza R, Murati A, Eclache V, Birg F, Birnbaum D, Mozziconacci MJ, Mecucci C, Chaffanet M.

Cancer Genet Cytogenet. 2007 Mar;173(2):154-8.

PMID:
17321332
41.

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.

Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M.

BMC Cancer. 2006 Oct 13;6:245.

42.

[Recent advances in the treatment of myelodysplastic syndromes].

Gelsi-Boyer V, Vey N.

Rev Med Interne. 2006 Aug;27(8):600-9. Epub 2006 Apr 7. Review. French.

PMID:
16713027
43.

t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera.

Murati A, Adélaïde J, Gelsi-Boyer V, Etienne A, Rémy V, Fezoui H, Sainty D, Xerri L, Vey N, Olschwang S, Birnbaum D, Chaffanet M, Mozziconacci MJ.

Leukemia. 2006 Jun;20(6):1175-8. No abstract available.

PMID:
16572202
44.

A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.

Adélaïde J, Pérot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C, Imbert M, Chaffanet M, Birnbaum D, Mozziconacci MJ.

Leukemia. 2006 Mar;20(3):536-7. No abstract available.

PMID:
16424865
45.

Comprehensive profiling of 8p11-12 amplification in breast cancer.

Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F, Esteyriès S, Adélaïde J, Esterni B, Henry C, Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauffret E, Jacquemier J, Bertucci F, Birnbaum D, Theillet C, Chaffanet M.

Mol Cancer Res. 2005 Dec;3(12):655-67.

46.

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.

Murati A, Gelsi-Boyer V, Adélaïde J, Perot C, Talmant P, Giraudier S, Lodé L, Letessier A, Delaval B, Brunel V, Imbert M, Garand R, Xerri L, Birnbaum D, Mozziconacci MJ, Chaffanet M.

Leukemia. 2005 Sep;19(9):1692-6. No abstract available.

PMID:
16034466
47.

ETV6 gene rearrangements in invasive breast carcinoma.

Letessier A, Ginestier C, Charafe-Jauffret E, Cervera N, Adélaïde J, Gelsi-Boyer V, Ahomadegbe JC, Benard J, Jacquemier J, Birnbaum D, Chaffanet M.

Genes Chromosomes Cancer. 2005 Sep;44(1):103-8.

PMID:
15887243

Supplemental Content

Loading ...
Support Center